OBR Peer-Spectives

In this episode of CANCER BUZZ from the Association of Community Cancer Centers (ACCC), we discuss how healthcare providers and policymakers can work together to pave the future of telehealth beyond the current public health emergency. Now that the barriers to telehealth have tumbled on an unprecedented scale, it’s doubtful future healthcare delivery will maintain […]

Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center and Arjun Balar, MD, Director, Genitourinary Medical Oncology Program, NYU Langone’s Perlmutter Cancer Center, discuss clinical progress in bladder cancer

Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center and Neeraj Agarwal, MD, Professor of Medicine, Huntsman Cancer Institute, Presidential Endowed Chair of Cancer Research , Co-Leader, HCI Experimental Therapeutics Program (CCSG Program), Director, Center of Investigational Therapeutics, Director, Genitourinary Oncology Program, Huntsman Cancer Institute, University of Utah, discuss clinical progress in prostate […]

Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center and Toni Choueiri, MD, Director of the Lank Center for Genitourinary (GU) Oncology at Dana-Farber Cancer Institute, discuss clinical progress in renal cell carcinoma (RCC)

Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center and Adam Brufsky, MD, PhD, Professor of Medicine, Associate Division Chief for the Division of Hematology/Oncology, UPMC, discuss clinical highlights from SABCS 2020

Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center and Mazyar Shadman, MD, MPH, Associate Professor, Clinical Research Division Fred Hutchinson Cancer Research Center, discuss clinical highlights in the treatment of CLL from ASH 2020

Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center and David Sallman, MD, Assistant Member, Department of Malignant Hematology, Moffitt Cancer Center discuss CAR T as it pertains to clinical advances in leukemia

Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center and Bradley McGregor, MD, Clinical Director, Lank Center for Genitourinary Oncology, Professor of Medicine, Harvard Medical School, discuss Checkmate-9ER and other I-O studies as they pertain to the management of RCC patients

Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center, and Victoria Villaflor, MD, Clinical Professor, Director Head and Neck Oncology at City of Hope, discuss unresectable stage III Non Small Cell Lung Cancer (www.azioinpractice.com)

Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center, and Geoffrey Ku, MD, Medical Oncologist, Memorial Sloan Kettering Cancer Center, discuss recent clinical developments in gastric and esophageal cancer

Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center, and Sara Hurvitz, MD, Associate Professor of Medicine, Geffen School of Medicine, UCLA, Medical Director, Jonsson Comprehensive Cancer Center Clinical Research Unit, discuss breast cancer patient types, challenges, and treatment advances

Roy Herbst, MD and Robert Figlin, MD discuss the implications of the recent ASCO20 presentation of the ADAURA study investigating the use of Tagrisso (osimertinib) in Stage I-III EGFR+ NSCLC patients

Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center, and David Ilson, MD, Attending Physician, Memorial Sloan Kettering Cancer Center, Professor of Medicine, Weill Cornell Medical College, discuss the progress in colon and rectal cancer presented at ASCO20

Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center, and Nancy Lin MD, Associate Professor of Medicine, Harvard Medical School Associate Chief, Division of Breast Oncology Dana-Farber Cancer Institute, discuss novel agents and recent clinical developments in breast cancer from ASCO20

Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center, and Edward Garon, MD, Director of Thoracic Oncology Program, Jonsson Comprehensive Cancer Center, Associate Professor of Medicine, David Geffen School of Medicine, UCLA, discuss promising agents in development for the management of NSCLC from ASCO20

Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center, and Constantine Tam, MD, Haematologist and Disease Group Lead, Low Grade Lymphoma and Chronic Lymphocytic Leukemia, Peter MacCallum Cancer Centre, discuss the progress in Waldenstrom macroglobulinemia

Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center, and Jeffrey A. Meyerhardt, Professor, Medicine, Harvard Medical School, Active Medical Staff, Medical Oncology, Dana-Farber Cancer Institute, discuss the progress in CRC presented at ASCO20

Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center, and Tian Zhang, MD, Assistant Professor of Medicine, Duke University School of Medicine, discuss the progress in RCC presented at ASCO GU ’20

Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center and BJ Rimel, MD, Assistant Professor, Obstetrics and Gynecology, discuss recent clinical studies in ovarian cancer and how recent developments are impacting the way ovarian cancer patients are treated

Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center and Lori Leslie, MD, Medical Oncologist, Regional Cancer Care Associates, discuss clinical highlights in the treatment of CLL

Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center and Michael Yang, MD, Department of Lymphoma and Myeloma, Division of Cancer Medicine, MD Anderson, discuss recent clinical advances in mantle cell lymphoma

Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center and Michael Jain, MD, Assistant Member, Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, discuss the role of CAR-T and the treatment of lymphoma and off-the-shelf CAR-T

Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center, and Daniel Petrylak, MD, Professor of Medicine, Medical Oncology and Urology, Co-Leader, Cancer Signaling Networks, Yale Cancer Center, discuss the progress in prostate cancer presented at ASCO GU ’20

Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center, and Zev Wainberg, MD, Assistant Professor of Medicine at UCLA and Co-Director of the UCLA GI Oncology Program, discuss the progress in colorectal cancer presented at ASCO GI ’20

Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center and Bradley Monk, MD, FACOG, FACS, Professor and Director of the Division of Gynecologic Oncology at Creighton University School of Medicine, discuss ovarian cancer clinical updates from ESMO 19

Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center and Marwan Fakih, MD, Professor, Department of Medical Oncology & Therapeutics Research, City of Hope, discuss colorectal cancer clinical updates from ESMO 19

Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center and Geoffry R. Oxnard, MD, Associate Professor of Medicine, Associate Professor of Medicine, Dana Farber Cancer Instituate, Harvard Medical School, discuss integrating liquid biopsies into lung cancer care